Patient Safety Guide for Erdafitinib and Enfortumab Vedotin: What to Look for and What to Report to Your Healthcare Team

Slides from Arjun Balar, MD on optimal selection of first-line treatment for patients with advanced urothelial cancer, from Clinical Care Options (CCO)

Arjun Balar, MD Released: May 6, 2021

Expert insight from Arjun Balar, MD, on choosing optimal first-line therapy for patients with advanced urothelial or bladder cancer, from Clinical Care Options (CCO)

Arjun Balar, MD Kaitlynn Francese, MSN, RN, OCN Physicians: maximum of 0.25 AMA PRA Category 1 Credits™ Registered Nurses: 0.25 Nursing contact hours Pharmacists: 0.25 contact hours (0.025 CEUs) Released: May 6, 2021 Expired: May 5, 2022

Expert insight from Arjun Balar, MD, on choosing optimal therapy for patients with advanced urothelial cancer after chemo and IO, from Clinical Care Options (CCO)

Arjun Balar, MD Kaitlynn Francese, MSN, RN, OCN Physicians: maximum of 0.25 AMA PRA Category 1 Credits™ Registered Nurses: 0.25 Nursing contact hours Pharmacists: 0.25 contact hours (0.025 CEUs) Released: May 4, 2021 Expired: May 3, 2022

Slides from Arjun Balar, MD on the role of antibody-drug conjugates in early stage urothelial cancer, from Clinical Care Options (CCO)

Arjun Balar, MD Released: May 4, 2021